Launch “Game of Stroke” by AZ Groeninge

GAME OF STROKE – by AZ Groeninge 

 

Every minute counts in a stroke, so it’s important that children can also act quickly That is why az groeninge, with the help of Belgian Stroke Council, is launching the Game of Stroke, a digital game for 6- to 10-year-olds Cat BEFAST takes them on an adventure and playfully teaches children to recognise symptoms of a stroke, such as a leg that no longer has any strength, strange talking, slanted mouth, … The cat also shows how children can help

Ready for play the game at azg.site/gameofstroke 

    BSC statement regarding the use of TNK for treatment of acute ischemic stroke

    The Belgian Stroke Council is currently awaiting a decision by FAGG and RIZIV/INAMI regarding marketing and reimbursement of tenecteplase (TNK) for treatment of acute ischemic stroke in Belgium.

    Based on the current evidence obtained from randomized, controlled trials comparing TNK with alteplase (tPA), the European Stroke Organisation (ESO) has stated that TNK (dosed at 0.25mg/kg) may be used as an alternative for tPA in eligible patients with acute ischemic stroke. The effectiveness and safety of TNK is comparable to tPA. Acute stroke patients with an occlusion of a large intracranial blood vessel may particularly benefit from TNK.

    For more information, we refer to the BSC opinion statement and the ESO guideline on the use of TNK, attached to this post.

    BSC opinion statement in dutch

    BSC opinion statement in french

    ESO guideline on TNK use

    Prevent, Treat and Support: a manifesto for stroke survivors

    The Stroke Alliance for Stroke ( SAFE) and the European Stroke Organisation (ESO) have published a manifesto outlining a number of keypoints to improve prevention, treatment and support for stroke patients across Europe. In the meantime, a letter has been sent to all Belgian members of the European Parliament and Belgian ministers of health, asking them to consider including these initiatives in their electoral programs. Read the manifesto here and the letter sent to our ministers here

    Remboursement Xarelto 2,5 mg

    We are delighted to announce that neurologists also have been recognised for the reimbursement of Xarelto 2.5mg in coronary artery disease (CAD) and peripheral artery disease PAD), since February 1, 2024.
    Furthermore, the duration of acceptance has been changed, since the 3-year limit has been withdrawn.

     

    Please find attached Bayer’s information letter: BE.XAR.VAE_Remboursement CADPAD_FR